1. Home
  2. JBDI vs RLYB Comparison

JBDI vs RLYB Comparison

Compare JBDI & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JBDI
  • RLYB
  • Stock Information
  • Founded
  • JBDI 1983
  • RLYB 2018
  • Country
  • JBDI Singapore
  • RLYB United States
  • Employees
  • JBDI N/A
  • RLYB N/A
  • Industry
  • JBDI
  • RLYB Biotechnology: Pharmaceutical Preparations
  • Sector
  • JBDI
  • RLYB Health Care
  • Exchange
  • JBDI Nasdaq
  • RLYB Nasdaq
  • Market Cap
  • JBDI 28.7M
  • RLYB 24.1M
  • IPO Year
  • JBDI 2024
  • RLYB 2021
  • Fundamental
  • Price
  • JBDI $1.02
  • RLYB $0.63
  • Analyst Decision
  • JBDI
  • RLYB Hold
  • Analyst Count
  • JBDI 0
  • RLYB 2
  • Target Price
  • JBDI N/A
  • RLYB N/A
  • AVG Volume (30 Days)
  • JBDI 59.2K
  • RLYB 250.8K
  • Earning Date
  • JBDI 01-01-0001
  • RLYB 11-06-2025
  • Dividend Yield
  • JBDI N/A
  • RLYB N/A
  • EPS Growth
  • JBDI N/A
  • RLYB N/A
  • EPS
  • JBDI N/A
  • RLYB N/A
  • Revenue
  • JBDI $8,445,000.00
  • RLYB $674,000.00
  • Revenue This Year
  • JBDI N/A
  • RLYB N/A
  • Revenue Next Year
  • JBDI N/A
  • RLYB N/A
  • P/E Ratio
  • JBDI N/A
  • RLYB N/A
  • Revenue Growth
  • JBDI N/A
  • RLYB 12.71
  • 52 Week Low
  • JBDI $0.49
  • RLYB $0.22
  • 52 Week High
  • JBDI $3.00
  • RLYB $1.24
  • Technical
  • Relative Strength Index (RSI)
  • JBDI 33.91
  • RLYB 53.09
  • Support Level
  • JBDI $1.11
  • RLYB $0.61
  • Resistance Level
  • JBDI $1.23
  • RLYB $0.72
  • Average True Range (ATR)
  • JBDI 0.12
  • RLYB 0.05
  • MACD
  • JBDI -0.03
  • RLYB 0.00
  • Stochastic Oscillator
  • JBDI 4.54
  • RLYB 33.33

About JBDI JBDI Holdings Limited Ordinary Shares

JBDI Holdings Ltd is a supplier of Reconditioned and new Containers in Singapore. Its products include Reconditioned and new steel drums, plastic drums, carboys and IBCs.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Share on Social Networks: